Collagen degradation in atherosclerotic plaques with thin fibrous caps renders them more prone to rupture. Fibroblast activation protein (FAP) plays a role in arthritis and tumour formation through its collagenase activity. However, the significance of FAP in thin-cap human fibroatheromata remains unknown.
Introduction
Rupture of the fibrous cap in advanced atherosclerotic plaques is a critical trigger of acute coronary syndromes (ACS) that may lead to myocardial infarction and sudden cardiac death. One of the key events in promoting plaque instability is the degradation of the fibrous cap, which exposes the underlying thrombogenic plaque core to the bloodstream, thereby causing thrombosis and subsequent vessel occlusion. 1 -3 Fibrous cap rupture is facilitated by proteases which cleave type I collagen, the primary load-bearing molecule in fibrous caps, leading to fibrous cap thinning and destabilization. 4 -7 Therefore, activated proteases, which localize to thin fibrous caps, have attracted attention as potential diagnostic and therapeutic targets. Candidate targets include matrix metalloproteinase (MMP)-2 and -9 and the cysteine protease cathepsin K each of which are enhanced in both stable and unstable lesions. 8 -11 Matrix metalloproteinase-2 and cathepsin K staining reveal diffuse localization throughout the plaque, whereas MMP-9 has been shown to colocalize with macrophages beneath the fibrous cap. 12 -14 Although these proteases have shown potential as markers of atherosclerotic plaques, their diffuse expression in all lesions -warrant careful assessment of their targeting potential towards clinically relevant unstable plaques. An ideal protease target would be specific to the rupture-prone fibrous cap; a site perhaps more easily accessible by intravenously injected targeting agents. Although MMPs and cysteine proteases have been well characterized as protease targets, the role of serine proteases in this context has not been investigated. Fibroblast activation protein (FAP) is a membrane-bound, constitutively active serine protease expressed by activated fibroblasts in epithelial tumour stroma, arthritis, and wound healing, but remains virtually undetectable in healthy tissues. 15 -17 Fibroblast activation protein is an enzyme that exhibits dipeptidyl peptidase IV activity, prolyl endopeptidase activity, and specificity for type I collagen. 17 -19 However, the role of FAP in atherosclerosis is unknown. The aim of this study was to characterize FAP expression in human atherosclerosis and examine its association with features of plaque instability. Moreover, we sought to determine the mechanism of FAP induction, its downstream effects, and the capacity of a neutralizing FAP-specific antibody. The graph reveals a significant increase in fibroblast activation protein expression in type II-III aortic plaques (n ¼ 9) and in type IV -V plaques (n ¼ 12) compared with plaque-free aortae (n ¼ 8).
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Methods
For the detailed Methods section, see Supplementary material online. 
Characterization of atherosclerotic plaques

Immunofluorescence and immunohistochemistry
Cross-sections from human ascending aortae (10 mm thickness) and paraffin-embedded sections of coronary plaques (4 mm thickness)
were mounted on glass slides. Tissue sections were labelled against FAP and cell-specific markers with purchased antibodies directed against CD68, von Willebrand factor (vWF), a-smooth muscle actin (aSMA), or type I collagen and visualization with either fluorescencelabelled secondary antibodies or biotin-labelled secondaries for immunostaining using an ABC staining kit for diaminobenzidine (Vector Labs, Burlingame, CA, USA).
Image analysis
For low-power imaging at spatial resolutions above 1 mm/pixel, a fluorescent microscope (DM60000B; Leica, Wetzlar, Germany) equipped with a fluorescent camera (DFC350 FX; Leica) was used. Colocalization analyses were performed at higher magnifications using a multichannel confocal microscope (TCS SP2; Leica) on a single optical plane.
Cells
Human aortic endothelial cells (HAEC) were isolated from biopsies of ascending aortae without macroscopic lesions obtained from patients undergoing operations for valve repair, human aortic smooth muscle cells (HASMC) were purchased (Promocell), and peripheral bloodderived monocytes were isolated from healthy subjects. Foam cells were generated by stimulating macrophages with 100 mg/mL of oxidized LDL (BT-910; BioConcept, Allschwil, Switzerland) for 48 h in serum-free macrophage medium (SFM; Gibco). Lipid uptake was assessed by Oil-red-O staining (O0624; Sigma-Aldrich). 
Fibroblast activation protein induction assays
Quiescent HASMC were treated with starvation media supplemented with 3, 5, 10, 20, and 40% macrophage-conditioned SFM for 48 h. To determine the effects of tumour necrosis factor a (TNFa) on FAP expression, quiescent HASMC were treated with starvation media supplemented with 20% macrophage-conditioned SFM and a TNFaneutralizing antibody (Ab6671; Abcam) or an IgG isotype control (Ab27478; Abcam) antibody. Recombinant human TNFa (300-01A; Peprotech) was used to induce FAP expression in quiescent HASMC in a dose-and time-dependent manner. Fibroblast activation protein levels were quantified by cell membrane enzyme-linked immunosorbent assay (see Supplementary material online, Figure S1 ).
Fibroblast activation protein-mediated type I collagen degradation assays
In situ zymography was performed on 5 mm cryosections of human aortic atherosclerotic plaques, which had been stained for FAP using a non-inhibitory antibody (F19). Sections were then incubated with an inhibitory antibody (A246) or isotype control (50 nM) overnight at 48C. Subsequently, sections were mounted in warm 1% Agarose in phosphate-buffered saline (PBS) supplemented with 10% directquenched type I collagen from bovine skin (D12060; Invitrogen) and imaged after 2 h at 378C using confocal microscopy. Image Quantification was performed as described in the Supplemental material online.
To evaluate the FAP-mediated type I collagen-specific cleavage, fulllength native human type I collagen isolated from human placenta (purity . 90%) was used (288; Yo Proteins). Type I collagen (100 ng/mL) was treated with recombinant human FAP (rhuFAP; 200 nM) for 18 h at 378C in PBS (pH ¼ 7.2) and compared with an untreated collagen control. A246 (50 ng/mL) was added to the solution and compared with an isotype control antibody IgG (Ab27478; Abcam) to validate the neutralizing capacity of A246. Samples were separated by electrophoresis and visualized by silver staining (ProteoSilver Silver Stain Kit, Sigma).
Statistical analyses
Histological and cell culture results were compared using one-way ANOVA and associations calculated by Pearson's correlation coefficient. Student's t-test was used for comparisons of zymography. All statistical analyses were performed using MatLab (Version, R2007b). Data are presented as mean + SD. Significance was accepted at the level of P , 0.05.
Results
Fibroblast activation protein is expressed by smooth muscle cells, but not macrophages in advanced human aortic plaques
Immunofluorescent stainings for FAP in adjacent cryosections revealed enhanced expression of FAP in fibroatheromata vs. plaque-free aortae ( Figure 1A) . Positive staining for FAP was virtually absent in healthy ascending aortae, whereas a step-wise increase was observed in type II-III and type IV-V plaques by western blot analyses ( Figure 1B ; see Supplementary material online, Figure S2 ) and quantitative image analysis ( Figure 1C and D) .
To characterize FAP-expressing cell types in human atherosclerotic plaques, we performed immunofluorescent co-stainings of FAP in macrophages (identified as CD68-positive cells), smooth muscle cells (aSMA-positive cells), and endothelial cells Fibroblast activation protein expression is enhanced in thin-cap vs. thick-cap human coronary atheromata
In order to determine the association of FAP with coronary fibrous cap thickness, we stained collagen applying the Masson method (stains collagen in blue) in rupture-prone human coronary arteries obtained from patients who died after myocardial infarction. On the basis of fibrous cap thickness, these specimens were characterized as thin-cap (,65 mm) or thick-cap (≥65 mm) fibroatheromata. Immunohistological and immunofluorescent stainings and subsequent confocal image analyses in adjacent sections revealed enhanced FAP expression in thin compared with thick fibrous caps ( Figure 4A and B) .
Fibroblast activation protein expression associates with the macrophage burden in human aortic atherosclerotic plaques
Immunofluorescence stainings revealed FAP expression in medial cells adjacent to macrophages in aortic fatty streaks ( Figure 5A) . To characterize the relationship between FAP and inflammation, we compared FAP and macrophage immunofluorescent signal intensity in human aortic plaques ( Figure 5B ). We observed a positive correlation between macrophage burden and FAP expression with plaque progression (R 2 ¼ 0.763; n ¼ 12; Figure 5C ).
Macrophage-derived tumour necrosis factor a induces fibroblast activation protein expression in cultured human aortic smooth muscle cells
To elucidate a signalling mechanism between macrophages and FAP-expressing HASMC, we exposed HASMC to macrophageconditioned media for 48 h to simulate conditions applicable to plaque inflammation. Cultured HASMC showed a dose- dependent increase in FAP expression in response to the macrophage-conditioned media with a maximal effect observed at 20% media concentration ( Figure 6A ) after 48 h. This effect was abolished when macrophage-conditioned media was supplemented with a TNFa-neutralizing antibody ( Figure 6B ). To confirm this paracrine effect of TNFa on FAP expression, experiments were repeated using recombinant human TNFa. Tumour necrosis factor a-mediated FAP expression was observed in a dose-and time-dependent manner, with a maximum response at 30 ng/mL after 48 h ( Figure 6C and D) . 
Fibroblast activation protein-mediated type I collagenase activity in aortic fibrous caps is inhibited by a fibroblast activation protein-neutralizing antibody
Immunofluorescence analyses revealed enhanced FAP expression in type I collagen-poor regions of aortic fibrous caps ( Figure 7A ). Aortic fibrous caps treated with an IgG control antibody showed a colocalization of FAP with cleaved DQ type I collagen, whereas Ab246-treated plaques demonstrated a significantly reduced colocalization of FAP with type I collagenase activity ( Figure 7B ). Confocal image analyses revealed that A246-treated fibrous caps exhibited decreased cleaved type I collagen at sites of FAP expression ( Figure 7C ). Type I collagenase activity of rhuFAP and the neutralizing capacity of A246 were demonstrated by incubation of native human type I collagen with rhuFAP in the presence of inhibiting antibody or isotype control ( Figure 7D ).
Discussion
The fibrous cap of an atherosclerotic plaque is essential for separating the bloodstream in the vessel lumen from its thrombogenic necrotic core. The mechanical strength of the fibrous cap is provided primarily by type I collagen, which is degraded by MMPs and cysteine proteases, both of which are associated with plaque instability and the occurrence of acute thrombotic events. 22 -26 This study links the constitutively active serine protease FAP to plaque progression and fibrous cap thinning and provides evidence that (i) FAP expression is enhanced in human aortic atheromata and in fibrous caps of thin-cap coronary plaques, (ii) FAP is expressed in HASMC and its expression correlates with macrophage burden, (iii) FAP expression is induced in HASMC by macrophage-derived TNFa via paracrine signalling, (iv) FAP cleaves collagen in fibrous caps of human atheromata, and (v) FAP-mediated type I collagenase activity is inhibited by an FAP-neutralizing antibody.
Numerous studies implicate matrix-degrading collagenases such as MMP-1, -2, and -9 as well as cysteine proteases such as cathepsins S and K in vascular remodelling and plaque rupture. 13, 23, 27 Our findings provide evidence that FAP is the first known smooth muscle cell-derived serine protease involved in collagen degradation in human atherosclerosis. Fibroblast activation protein expression was particularly enhanced in fibrous caps of thin-cap Taken together, we found that FAP expression is induced by macrophage-derived TNFa in HASMC, associates with thin-cap human coronary plaques, and contributes to type I collagen breakdown in fibrous caps. Thus, FAP expression in thin-cap coronary plaques and endothelial cells renders this target attractive for further investigation in patients with ACS. Along this line, we plan to investigate whether soluble FAP may be a biomarker for ACS. Moreover, our present findings demonstrate that FAPmediated collagenolysis is induced by inflammatory cues and may be blocked by neutralizing antibodies. At the experimental level, studies using genetic or pharmacological modulation of FAP will shed light onto the causal role of FAP in atherogenesis and its potential use as a target in atherosclerosis and other inflammatory diseases such as rheumatoid arthritis and tumour formation.
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